TY - JOUR T1 - Molecular beacons allow specific RT-LAMP detection of B.1.1.7 variant SARS-CoV-2 JF - medRxiv DO - 10.1101/2021.03.25.21254356 SP - 2021.03.25.21254356 AU - Scott Sherrill-Mix AU - Gregory D. Van Duyne AU - Frederic D. Bushman Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254356.abstract N2 - Over the course of the COVID-19 pandemic, several SARS-CoV-2 genetic variants of concern have appeared and spread throughout the world. Detection and identification of these variants is important to understanding and controlling their rapid spread. Current detection methods for a particularly concerning variant, B.1.1.7, require expensive qPCR machines and depend on the absence of a signal rather than a positive indicator of variant presence. Here we report an assay using a pair of molecular beacons paired with reverse transcription loop mediated amplification to allow isothermal amplification from saliva to specifically detect B.1.1.7 and other variants which contain a characteristic deletion in the gene encoding the viral spike protein. This assay is specific, affordable and allows multiplexing with other SARS-CoV-2 LAMP primer sets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Penn Center for Research on Coronaviruses and Other Emerging Pathogens.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Pennsylvania Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is included in the paper. ER -